Half Year Longitudinal Seroprevalence of SARS-CoV-2-antibodies and Rule Compliance in German Hospital Employees

Herzberg, Jonas; Vollmer, Tanja; Fischer, Bastian; Becher, Heiko; Becker, Ann‐Kristin; Sahly, Hany; Honarpisheh, Human; Guraya, Salman Yousuf; Strate, Tim; Knabbe, Cornelius

doi:10.1101/2021.03.29.21254538

Cited by 6 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All hospital employees were invited to participate during the first phase of the pandemic, so that the longitudinal trial began in April 2020. During that phase, a longitudinal evaluation of seroprevalence and PCR-positivity was performed followed by a half-year seroprevalence evaluation in October 2020 [18].…”

Section: Methodsmentioning

confidence: 99%

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

Herzberg

Vollmer

Fischer

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare. Methods We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine. Results We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p=0.006) Conclusion Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.

show abstract

Section: Methodsmentioning

confidence: 99%

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

Herzberg

Vollmer

Fischer

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Within the study cohort presented here, smoking, increased age and BMI have previously been shown to have a negative impact in studies involving two doses of BNT162b2 [28] or 9 months after vaccination, respectively [2]. This could not be seen in the results presented here (Table 3).…”

Section: Factors Causing a Reduced Immune Responsementioning

confidence: 48%

Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine – a prospective observational study

Herzberg

Fischer

Becher

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background Since the introduction of various vaccines against SARS-CoV-2 at the end of 2020, rates of infection have continued to climb worldwide. This led to the establishment of a third dose vaccination in several countries, known as a booster. To date, there has been little real-world data about the immunological effect of this strategy. Methods We compared the humoral- and cellular immune response before and after the third dose of BioNTech/Pfizer vaccine BNT162b2, following different prime-boost regimes. Humoral immunity was assessed by determining anti-SARS-CoV-2 binding antibodies using a standardized quantitative assay. In addition, neutralizing antibodies were measured using a commercial surrogate ELISA-assay. Interferon-gamma release was measured after stimulating blood-cells with SARS-CoV-2 specific peptides using a commercial assay to evaluate the cellular immune response. Results The median antibody level increased significantly after the third dose to 2663.1 BAU/ml vs. 101.4 BAU/ml (p < 0.001) before administration of the boosting dose. This was also detected for neutralizing antibodies with a binding inhibition of 99.68% ± 0.36% vs. 69.06% ± 19.88% after the second dose (p < 0.001). 96.3% of the participants showed a detectable T-cell-response after the third dose with a mean interferon-gamma level of 2207.07 mIU/ml ± 1905 mIU/ml. Conclusion This study detected a BMI-dependent increase after the third dose of BNT162b2 following different vaccination protocols, whereas all participants showed a significant increase of their immune response. This, in combination with the limited post-vaccination-symptoms underlines the potential beneficial effect of a BNT162b2-boosting dose.

show abstract

Seroprevalence of SARS-CoV-2 Antibodies in Employees of Three Hospitals of a Secondary Care Hospital Network in Germany and an Associated Fire Brigade: Results of a Repeated Cross-Sectional Surveillance Study Over 1 Year

Hildebrandt

Hökelekli

Uflacker

et al. 2022

IJERPH

View full text Add to dashboard Cite

Healthcare workers (HCWs) are playing a vital role in the current SARS-CoV-2 pandemic. This study investigated how infection spreads within three local hospitals and an associated fire brigade in Germany by testing employees for the presence of SARS-CoV-2 IgG antibodies over one year. The three observational periods corresponded to the initial three pandemic waves: first wave: June–September 2020, second wave: October 2020–January 2021, and third wave: February–June 2021. We analysed 3285 serum samples of 1842 employees, which represents 65.7% of all employees. Altogether, 13.2% employees were seropositive: 194/1411 HCWs (13.7%) and 49/431 non-HCWs (11.4%) with a clear increase of seroprevalence from the first (1.1%) to the second (13.2%) and third (29.3%) pandemic wave. HCWs presumably had an additional occupational risk for infection in the second and third wave due to an increase of infection pressure with more COVID-19 patients treated, showing possible weak points in the recommended infection prevention strategy.

show abstract

Half Year Longitudinal Seroprevalence of SARS-CoV-2-antibodies and Rule Compliance in German Hospital Employees

Cited by 6 publications

References 36 publications

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine – a prospective observational study

Seroprevalence of SARS-CoV-2 Antibodies in Employees of Three Hospitals of a Secondary Care Hospital Network in Germany and an Associated Fire Brigade: Results of a Repeated Cross-Sectional Surveillance Study Over 1 Year

Contact Info

Product

Resources

About